The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
Globally, BRUKINSA is approved in more than 70 countries
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
